Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.35 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 3/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17294153 | 0.81 | LMNA (0.40) | TP53LMNAKDM4EALDH1A1CYP3A4 | |
| SCHEMBL17294138 | 0.77 | LMNA (0.50) | TP53LMNAKDM4EALDH1A1CYP3A4 | |
| SCHEMBL20067185 | 0.77 | HDAC1 (0.32) | TP53LMNAKDM4EALDH1A1CYP3A4 | |
| SCHEMBL17294150 | 0.73 | LMNA (0.41) | TP53LMNAKDM4EALDH1A1CYP3A4 | |
| SCHEMBL3684608 | 0.72 | LMNA (0.54) | TP53LMNAKDM4EALDH1A1CYP3A4 | |
| SCHEMBL17294163 | 0.71 | MMP2 (0.39) | TP53LMNAKDM4EALDH1A1CYP3A4 | |
| SCHEMBL3855502 | 0.70 | LMNA (0.41) | TP53LMNAKDM4EALDH1A1CYP3A4 | |
| SCHEMBL17294151 | 0.69 | TP53 (0.41) | TP53LMNAALDH1A1MMP9MMP8 | |
| SCHEMBL17294193 | 0.69 | MMP2 (0.45) | TP53LMNAKDM4EALDH1A1CYP3A4 | |
| SCHEMBL17294188 | 0.69 | TP53 (0.34) | TP53LMNAMMP9MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3148983-A1 | N-HYDROXYLAMINO-BARBITURIC ACID DERIVATIVES AS NITROXYL DONORS | The Johns Hopkins University (US) | 2017-04-05 | — | — | EP | claimed |
| US-9464061-B2 | N-hydroxylamino-barbituric acid derivatives | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-10-11 | — | — | US | claimed |
| US-20160060229-A1 | N-HYDROXYLAMINO-BARBITURIC ACID DERIVATIVES | NATIONAL SCIENCE FOUNDATION | 2016-03-03 | — | — | US | claimed |
| WO-2015183838-A1 | N-HYDROXYLAMINO-BARBITURIC ACID DERIVATIVES AS NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-12-03 | — | — | WO | claimed |
| EP-3148983-A1 | N-HYDROXYLAMINO-BARBITURIC ACID DERIVATIVES AS NITROXYL DONORS | The Johns Hopkins University (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9464061-B2 | N-hydroxylamino-barbituric acid derivatives | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464061-B2 | N-hydroxylamino-barbituric acid derivatives | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464061-B2 | N-hydroxylamino-barbituric acid derivatives | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160060229-A1 | N-HYDROXYLAMINO-BARBITURIC ACID DERIVATIVES | NATIONAL SCIENCE FOUNDATION | 2016-03-03 | — | — | US | disclosed |
| US-20160060229-A1 | N-HYDROXYLAMINO-BARBITURIC ACID DERIVATIVES | NATIONAL SCIENCE FOUNDATION | 2016-03-03 | — | — | US | disclosed |
| US-20160060229-A1 | N-HYDROXYLAMINO-BARBITURIC ACID DERIVATIVES | NATIONAL SCIENCE FOUNDATION | 2016-03-03 | — | — | US | disclosed |
| WO-2015183838-A1 | N-HYDROXYLAMINO-BARBITURIC ACID DERIVATIVES AS NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-12-03 | — | — | WO | disclosed |
| WO-2015183838-A1 | N-HYDROXYLAMINO-BARBITURIC ACID DERIVATIVES AS NITROXYL DONORS | THE JOHNS HOPKINS UNIVERSITY (US) | 2015-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060229-A1 | N-HYDROXYLAMINO-BARBITURIC ACID DERIVATIVES | TNNT2, TNNI3, TNNC1 | TP53 4139/4885LMNA 1383/4885KDM4E 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.